To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.
Expert Interview Asthma
The U-BIOPRED Study
An expert interview with Ian Adcock
Professor of Respiratory Cell and Molecular Biology, Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK
Ian Adcock is Professor of Respiratory Cell and Molecular Biology and Head of the Molecular Cell Biology Group at the National Heart and
Lung Institute, Imperial College London, UK. He also holds an honorary research position at the Royal Brompton Hospital, enabling him to
translate the basic research activities into the clinical environment.
Keywords Severe asthma, adults, multi-omics, systems
biology, clinical traits, sub-phenotypes,
bioinformatics Disclosure: Ian Adcock was supported by U-BIOPRED.
U-BIOPRED is supported through an Innovative Medicines
Initiative Joint Undertaking under grant agreement no.
115010, resources of which are composed of financial
contribution from the European Union’s Seventh
Framework Programme (FP7/2007-2013) and EFPIA
companies’ in kind contribution (www.imi.europa.eu). We
would also like to acknowledge help from the IMI funded
eTRIKS project (EU Grant Code No.115446). This is an
expert interview piece and as such has not undergone
the journal’s standard peer review process. No funding
was received for the publication of this article.
Authorship: All named authors meet the International
Committee of Medical Journal Editors (ICMJE) criteria
for authorship of this manuscript, take responsibility
for the integrity of the work as a whole, and have
given final approval for the version to be published.
Open Access: This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.
Received: 14 February 2017
Published Online: 26 July 2017
Citation: European Respiratory & Pulmonary Diseases,
2017;3(1):15–6 Corresponding Author: Ian Adcock, Faculty of
Medicine, National Heart & Lung Institute, Imperial College
London, UK. E: firstname.lastname@example.org
P rofessor Adcock obtained a degree in biochemistry and physiology from the University of
London and later completed a PhD in pharmacology from St Thomas’ Hospital, London,
on the role of nuclear receptors on sexual dimorphic patterns in the rat. He performed
postdoctoral training at the Medical Research Council (MRC) Brain Metabolism Unit with Professors
Tony Harmar and George Fink, and in the Protein Science Laboratory at St Georges’ Hospital with
Professor Brian Austen. He joined Professor Peter Barnes at the National Heart and Lung Institute
in 1990 to undertake research on the effects of corticosteroids on inflammatory mediators in
asthma and chronic obstructive pulmonary disease (COPD). This remains his major research
area, along with a long-term interest in the mechanisms underlying relative steroid insensitivity in
severe asthma and COPD.
Professor Adcock is an internationally recognised scientist in the field of airways disease and
inflammation. He has authored and co-authored over 230 scientific articles and has served on
the editorial boards of several journals. He has worked as an expert member on national grant-
awarding organisations including the UK MRC, the US National Institues of Health (NIH), the
Australian National Health and Medical Research Council (NHMRC), the French Agence Nationale
de la Recherche (ANR), the Norwegian Research Council and the Medical Research Council of
Canada. He has served on the European Respiratory Society (ERS) Council and is currently a
member of the ERS Executive Committee and Scientific Programme Committee and Head of the
ERS Assembly 5 (Airways Disease).
Professor Adcock is a principal investigator in the Medical Research Council/Asthma UK Centre in
Allergic Mechanisms of Asthma and in the Wellcome Trust Respiratory Infections Centre. His recent
research has been funded by grants from the Medical Research Council, Wellcome Trust, the
British Heart Foundation, the Royal Society, the European Union, the Biotechnology and Biological
Sciences Research Council, Engineering and Physical Sciences Research Council and industrial
collaborators. He is also a principal investigator in the European consortium Unbiased BIOmarkers
in PREDiction of respiratory disease outcomes (U-BIOPRED) on mechanisms of severe asthma
that is funded through the Innovative Medicine Initiative of the European Union and European
Federation of Pharmaceutical Industries and Associations.
Q: Can you tell us a little about the aims of the U-BIOPRED study?
U-BIOPRED is a European consortium of over 20 academic institutions, 11 pharmaceutical
companies and six patient organisations, funded by the Innovative Medicines Initiative (IMI),
whose aim is the better characterisation of severe asthma. It is particularly centered on
TOU CH MED ICA L MEDIA